Most people with multiple sclerosis who receive treatment today can expect to live into their 60s, 70s, or beyond. Older studies estimated MS shortened life by about 7 years on average, but more recent research suggests the gap may be as small as 2 years, thanks largely to treatments that have become available in the last two decades. The picture varies significantly depending on how much disability a person accumulates over time, which is exactly where treatment makes the biggest difference.
What the Numbers Actually Look Like
A large study tracking MS patients over decades found that those diagnosed with minimal to moderate disability, with an average age of about 33, had roughly 31 years of remaining life expectancy. That puts their expected lifespan at nearly 64. Those numbers reflect a broad population that includes people diagnosed in earlier eras with fewer treatment options, so people starting modern therapies today are likely to do better.
The critical factor isn’t the diagnosis itself. It’s how much disability accumulates. People who maintain the ability to walk independently have decades ahead of them. Life expectancy shortens more steeply at higher levels of disability: those who can still walk short distances but struggle with daily tasks average about 17 more years, while those who need a walking aid average around 13. The takeaway is that keeping disability low is the single most important factor in longevity with MS, and that’s the primary goal of treatment.
How Treatment Changes the Trajectory
About 85% of people with MS start with the relapsing-remitting form, where symptoms flare up and then partially or fully recover. Without treatment, many of these patients eventually transition to secondary progressive MS, where disability accumulates steadily without clear relapses. This transition is where much of the long-term damage happens.
Modern disease-modifying therapies significantly reduce the chance of that transition. Research published in the New England Journal of Medicine found that starting highly effective therapies within five years of disease onset meaningfully lowered the rate of conversion to progressive MS. Even older injectable therapies reduced conversion by 29% compared to no treatment. The newer, more potent therapies appear to do considerably better, though long-term data is still maturing. Starting treatment early, before significant disability sets in, gives you the best chance of staying in the lower-disability categories where life expectancy is closest to normal.
What Shortens Life in MS
In a 60-year study of MS patients, about 56% of deaths were attributed directly to MS itself, typically from complications of severe disability like respiratory infections, pressure injuries, or difficulty swallowing. The remaining deaths came from the same causes that affect the general population: heart disease, cancer, stroke. But certain common health conditions carry extra risk when combined with MS.
Diabetes, high blood pressure, heart disease, and chronic lung disease are all more strongly associated with death in people with MS than in the general population. This means managing these conditions isn’t just generally good advice; it’s disproportionately important if you have MS. Staying physically active to whatever degree you can, managing blood sugar and blood pressure, and not smoking all have an outsized impact on your long-term outlook.
Mental Health and Survival
Depression and anxiety are common in MS, affecting a large portion of patients at some point. This isn’t just a quality-of-life issue. It has real consequences for survival. Estimates suggest that up to 15% of MS deaths are due to suicide, a strikingly high figure that reflects the psychological burden of living with a chronic, unpredictable neurological condition. People with both MS and anxiety are at particularly elevated risk for suicidal thoughts.
Treating depression and anxiety in MS isn’t optional or secondary. It’s as important as disease-modifying therapy for long-term survival. If you’re experiencing persistent sadness, hopelessness, or thoughts of self-harm, that deserves the same urgency as a new relapse.
What Disability Levels Mean for Life Expectancy
Neurologists track MS disability using a scale from 0 to 10. The data on how each level correlates with remaining lifespan is striking in how clearly it shows that preventing disability progression is the key to living longer:
- Minimal disability (score 3.5 or lower): About 31 years of remaining life from an average age of 33.
- Moderate disability, still walking independently (score 4 to 5.5): About 17 years remaining from an average age of 47.
- Needs a walking aid (score 6 to 6.5): About 13 years remaining from an average age of 51.
- Unable to walk even with aid (score 7 to 7.5): About 7.6 years remaining from an average age of 58.
- Unable to stand, limited self-care (score 8 to 8.5): About 4.6 years remaining from an average age of 62.
- Bedridden (score 9 or higher): About 1 year remaining from an average age of 71.
These numbers look sobering at the higher end, but the crucial point is that most treated patients never reach the severe categories. The entire purpose of early, aggressive treatment is to keep you in the top rows of that list for as long as possible, ideally for life.
Why Today’s Outlook Is Better Than the Data Suggests
Nearly every long-term survival study includes patients diagnosed in the 1980s, 1990s, or early 2000s, when treatment options were limited or nonexistent. The first MS therapy wasn’t approved until 1993, and the more powerful treatments only became widely used in the 2010s. This means the life expectancy statistics you see today are weighted down by outcomes from an era of worse care.
Someone diagnosed today has access to more than 20 disease-modifying therapies, MRI monitoring that catches new disease activity before symptoms appear, and a growing understanding of how lifestyle factors like exercise, vitamin D, and smoking cessation influence progression. The 7-year life expectancy gap that older studies reported is almost certainly shrinking further for people who start effective treatment early and manage their overall health. The 2-year gap reported in more recent research likely reflects reality more accurately for today’s patients, and even that number may continue to narrow.